Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases

Phase 4

Completed

• Conditions: Neoplasm Metastasis
• Interventions: Drug: Zoledronic acid

• Registration Number: NCT00434317
• Lead Sponsor: Novartis

Brief Summary

This study will evaluate the safety, tolerability and efficacy of zoledronic acid administered intravenously every 3-4 weeks in patients with bone metastases from either breast cancer or prostate cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-08
• Study First Submitted: 2007-02-09
• Study First Submitted QC: 2007-02-09
• Study First Posted: 2007-02-13
• Primary Completion: 2008-04
• Status Verified: 2017-02
• Last Update Submitted: 2017-02-21
• Last Update Posted: 2017-02-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
ZOL446	Zoledronic acid	-

Primary Outcome Measures

Name	Time	Method
Measurement of pain assessed by a Visual Analogue Scale (VAS)	throughout the study

Secondary Outcome Measures

Name	Time	Method
Quality of Life assessment at baseline and last visit	throughout the study

Trial Locations

Locations (1)

Novartis Investigative Site; 🇭🇺 Szekesfehervar, Hungary